Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening

Emiel Vanhulle a, Joren Stroobants a, Becky Provinciael a, Anita Camps a, Sam Noppen a, Piet Maes b, Kurt Vermeire a, *

a KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49, 3000, Leuven, Belgium
b KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, Herestraat 49, 3000, Leuven, Belgium

ARTICLE INFO

Keywords:
Glioblastoma
U87 cell line
SARS-CoV-2
Antiviral screen
Omicron
CPE

ABSTRACT

Despite the great success of the administered vaccines against SARS-CoV-2, the virus can still spread, as evidenced by the current circulation of the highly contagious Omicron variant. This emphasizes the additional need to develop effective antiviral countermeasures. In the context of early preclinical studies for antiviral assessment, robust cellular infection systems are required to screen drug libraries. In this study, we reported the implementation of a human glioblastoma cell line, stably expressing ACE2, in a SARS-CoV-2 cytopathic effect (CPE) reduction assay. These glioblastoma cells, designated as U87.ACE2+, expressed ACE2 and cathepsin B abundantly, but had low cellular levels of TMPRSS2 and cathepsin L. The U87.ACE2+ cells fused highly efficiently and quickly with SARS-CoV-2 spike expressing cells. Furthermore, upon infection with SARS-CoV-2 wild-type virus, the U87.ACE2+ cells displayed rapidly a clear CPE that resulted in complete cell lysis and destruction of the cell monolayer. By means of several readouts we showed that the U87.ACE2+ cells actively replicate SARS-CoV-2. Interestingly, the U87.ACE2+ cells could be successfully implemented in an MTS-based colorimetric CPE reduction assay, providing IC50 values for Remdesivir and Nirmatrelvir in the (low) nanomolar range. Lastly, the U87.ACE2+ cells were consistently permissive to all tested SARS-CoV-2 variants of concern, including the current Omicron variant. Thus, ACE2 expressing glioblastoma cells are highly permissive to SARS-CoV-2 with productive viral replication and with the induction of a strong CPE that can be utilized in high-throughput screening platforms.

1. Introduction

Undoubtedly, the current coronavirus disease 2019 (COVID-19) pandemic has not only posed a serious threat to the international health, but it has also impacted people’s daily lifestyle and work, and the global economy. Since its outbreak in December 2019, SARS-CoV-2, the causative agent of COVID-19, has quickly spread around the world, leading to over 400 million confirmed cases and more than 5.8 million deaths worldwide as of February 11, 2022 (https://covid19.who.int/). Despite the great success of the current vaccines against SARS-CoV-2, we still cannot control the spread of new variants and/or prevent re-infections. This emphasizes the urgent need to develop effective antiviral countermeasures.

Major efforts are ongoing to develop novel therapeutics for COVID-19 treatment and/or effective prophylactic approaches to prevent viral spread (Yadav et al., 2021). In the context of early preclinical studies for SARS-CoV-2 antiviral assessment, screening platforms for drug libraries rely on the use of robust cellular infection systems, mostly based on immortalized cell lines originating from respiratory, but most often non-respiratory, tissues (Murgolo et al., 2021; Uemura et al., 2021; Chiu et al., 2022; Ramirez et al., 2021; Grau-Exposito et al., 2022; Ko et al., 2021; Chu et al., 2020). In fact, many initial screenings for SARS-CoV-2

Abbreviations: ACE2, Angiotensin-Converting Enzyme 2; CC, cytotoxic concentration; COVID-19, coronavirus disease 2019; CPE, cytopathic effect; CTS, cathepsin; MFI, mean fluorescence intensity; MOI, multiplicity of infection; OD, optical density; RdRp, RNA dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S, Spike; TMPRSS2, Transmembrane protease, serine 2.

* Corresponding author.

E-mail address: kurt.vermeire@kuleuven.be (K. Vermeire).

https://doi.org/10.1016/j.antiviral.2022.105342

Received 13 February 2022; Received in revised form 12 April 2022; Accepted 11 May 2022
Available online 18 May 2022

0166-3542/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
antivirals have largely utilized the African green monkey kidney cell line Vero E6 as the host cell. However, it is known that Vero E6 cells exploit intrinsic nonspecific endocytic mechanisms for virus uptake and viral entry (Murgolo et al., 2021). Furthermore, these cells have a low expression of angiotensin converting enzyme 2 (ACE2), the main virus receptor (Hoffmann et al., 2020; Wu et al., 2020a; Zhou et al., 2020; Wrapp et al., 2020; Yan et al., 2020), and are deficient in expressing TMPRSS2, a membrane-anchored serine protease localized to the plasma membrane that is involved in the activation of the viral Spike (S) protein for cell surface membrane fusion (Hoffmann et al., 2020; Laporte et al., 2021; Bestle et al., 2020). In addition, SARS-CoV-2 uses an alternative route of cell entry via the endocytic pathway, in which endosomal cysteine proteases, such as cathepsin L (CTSL) and cathepsin B (CTSB) are able to substitute for TMPRSS2 to cleave and prime the S protein into its fusogenic state (Shang et al., 2020; Evans and Liu, 2021). Notably, reports on current circulating SARS-CoV-2 variants of concern demonstrate that Omicron infection is not enhanced by TMPRSS2 but is largely mediated via the endocytic pathway (Zhao et al., 2021; Meng et al., 2022).

Evaluation of virus-induced cytopathic effect (CPE) is a low-cost read-out for a quick and robust analysis in antiviral screening platforms. However, not every cell type permissive to SARS-CoV-2 infection will present CPE during effective virus replication. Also, the characteristics of CPE is cell type and virus dependent, ranging from mild damaging events such as cell rounding and detachment, over cell degeneration, to severe syncytium formation. The latter may ultimately result in cell lysis and complete destruction of the integrity of the cell monolayer.

The astroglioma cell line U87 has been successfully used in previous research on human deficiency virus (HIV) (Princen et al., 2004; Hatse et al., 2001). Upon infection with HIV, these receptor-transfected U87 cells present a remarkable full-blown CPE that could be used as an easy readout in antiviral screening assays for HIV. Based on these characteristics, we explored in our current study the use of U87 cells for the infection with SARS-CoV-2. By means of several readouts we show that U87 cells that are stably expressing ACE2 (U87.ACE2+) cells, are highly permissive for SARS-CoV-2 with productive viral replication and with the induction of a strong CPE that can be utilized in high-throughput screening platforms.

2. Materials and methods

2.1. Cell lines and virus strains

Cell lines. Human Embryonic Kidney 293T (HEK293T) cells (cat n° CRL-3216), African green monkey kidney Vero E6 cells (cat n° CRL-1586), Human adenocarcinomic alveolar epithelial cells A549 (cat n° CCL-185), Human adenocarcinomic bronchial epithelial cells Calu3 (cat n° HTB-55) and human glioblastoma U87 MG cells (cat n° HTB-14) were obtained from ATCC as mycoplasma-free stocks and grown in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS; HyClone). Cell lines were maintained at 37 °C in a humidified environment with 5% CO2. Cells were passaged every 3–4 days.

Viruses. Severe Acute Respiratory Syndrome coronavirus 2 isolates (SARS-CoV-2) were recovered from nasopharyngeal swabs of RT-qPCR-confirmed human cases obtained from the University Hospital Leuven (Leuven, Belgium). SARS-CoV-2 viral stocks were prepared by inoculation of confluent Vero E6 cells as described in detail in a recent report (Vanhulle et al., 2022).

Recombinant SARS-CoV-2-GFP virus (Wuhan strain), as described in (Thi Nhu Thao et al., 2020), was a kind gift from Dr. Volker Thiel (University of Bern, Switzerland).

2.2. Antibodies and compounds

Antibodies. The following antibodies were used for western blotting: ACE2 Polyclonal Goat IgG (cat n° AF933, R&D systems), Cathepsin B Monoclonal Mouse IgG1 (cat n° MA5-32651, Thermo Fisher Scientific), Cathepsin L Monoclonal Mouse IgG1 (cat n° BMS166, Thermo Fisher Scientific), anti-clathrin (cat n° 610500, BD transduction laboratories), anti-β-actin (cat n° MA1-140, Invitrogen), HRP-labeled goat anti-mouse immunoglobulin (cat n° P0447, Dako). The following antibodies were used for flow cytometry: rabbit monoclonal SARS-CoV-2 spike-specific antibody (Cat. n° 40592-R001, Sino Biological), rabbit polyclonal SARS-CoV-2 nucleocapsid-specific antibody (Cat. n° GTX135537, GeneFex), fluorescent-labeled Alexa Fluor 647 (AF647) goat anti-Rabbit IgG monoclonal antibody (Cat. n° 4414, Cell Signaling Technologies).

Compounds. Monophosphoramidate prodruk Remdesivir GS-5734 (Cat. n° 469411000, Acros Organics); Molnupirvir (MK-4482 or EIDD-2801), a nucleoside analogue prodruk (Cat. n° S8969, Bio-Connect); Nirmatrelvir (PF-07321332), an irreversible inhibitor of SARS-CoV-2 viral main protease Mpro (Cat. n° S9866, Bio-Connect); purified SARS-CoV-2 spike-specific monoclonal rabbit primary antibody R001 (Cat. n° 40592-R001, Sino Biological).

2.3. Plasmids

Second generation lentiviral support plasmids pMD2.G and pSPAX2 were obtained from Addgene (www.addgene.org, Cat. n° 12259 and 12260, respectively). Cell lines expressing ACE2 were made by second generation lentiviral transduction with a lentiviral transfer vector containing the human ACE2 coding sequence. Using the NEBuilder HiFi DNA assembly cloning kit (NEB), ACE2, derived from a pcDNA3.1-hACE2 vector (Cat. n° 145033, Addgene), was inserted into a pLent6.3 vector (Thermo Fisher Scientific) in which the Cytomegalovirus (CMV) immediate-early enhancer/promoter region was replaced with a 0.6 kb minimal Ubiquitous Chromatin Opening Element (UCEO) sequence and a Spleen Focus Forming Virus (SFFV) promoter derived from pMM0001 (Cat. n° 85969, Addgene). An internal ribosomal entry site (IRES) was inserted behind the ACE2 sequence via restriction digestion of a pEF1a-IRES vector (Cat. n° 631970, Takara Bio Inc.) with Nhel-HF and Sall-HF (NEB). A synthesized fragment (Integrated DNA Technologies [IDT]) containing ten betasheets of a modified mNeonGreen and a porcine teschovirus-1 2A peptide (P2A) coding sequence was inserted between the IRES sequence and the Basticidin resistance cassette. pCAGGS.SARS-CoV-2.SΔ19.fpl.mNG2(11) opt was generated through gibson assembly (NEBuilder, New England Biolabs) of a pCAGGS vector backbone cleaved using EcoRV-HF and HindIII-HF (New England Biolabs) and a PCR fragment of a codon-optimized SARS-CoV-2 Wuhan spike protein with a C-terminal 19 amino acid deletion as described in (Ou et al., 2020). A 12 amino acid flexible protein linker and a modified 11th betasheet of mNeonGreen (Feng et al., 2017) were added at its C-Termminus. pcDNA3.1.mNG2(1–10) was generated through gibson assembly (NEBuilder, New England Biolabs) of a pcDNA3.1 vector (Thermo Fisher Scientific), amplified by PCR, and a PCR fragment of the first 10 betasheets of a modified mNeonGreen, synthesized by Genscript. Plasmids were sequence-verified with Sanger sequencing (Macrogen Europe, Amsterdam, The Netherlands) before use.

2.4. Lentiviral transduction of ACE2

For lentivirus production, 50–70% confluent HEK293T cells in T-25 flasks were transfected with Lipofectamine LTX & PLUS Reagent (Thermo Fisher Scientific). LTX solution and transfection mixes containing 3 μg of lentiviral ACE2 vector, 5.83 μg of pSPAX2 vector, 3.17 μg of pMD2.G vector and 12 μL PLUS reagent were prepared in serum-free Opti-MEM (Thermo Fisher Scientific). Following a 5-min incubation at room temperature, solutions were mixed and incubated for an additional
20 min. Cell medium was replaced with 5 mL of fresh medium, after which transfection complexes were added, followed by a 21-h incubation at 37 °C. Next, sodium butyrate (10 mM) was added, and cells were incubated for an additional 3 h, after which the medium was replaced with 5 mL of fresh medium. Virus-containing supernatants were harvested into 15 mL conical tubes 24 h after sodium butyrate addition and centrifuged at 2,000 g for 15 min at 4 °C to pellet cell debris. Transduction of cell lines with the harvested lentivirus was performed according to the ViraPower HiPerform T-Rex Gateway Expression System (Thermo Fisher Scientific) manufacturer’s protocol. One μg/ml Polybrene (Sigma-Aldrich) was used to increase transduction efficiency. Following transduction, cell medium was supplemented with 10 μg/ml blasticidin (InvivoGen) during passing. Monoclonal cell populations were generated by seeding 96-well plates with a dilute cell solution of 0.5 cells/well, monitoring wells with monoclonal cell growth and expanding to larger culture vessels.

2.5. Immunoblotting

Cells were collected and lysed in ice-cold Nonidet P-40 lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 1% Nonidet P-40) supplemented with 100x Complete Protease Inhibitor (Roche) and 250x PMSF Protease Inhibitor (100 mM in dry isopropanol, Thermo Fisher Scientific). Cell lysates were centrifuged at 17,000 g for 10 min at 4 °C to pellet nuclei and debris. For SDS gel electrophoresis, supernatant was boiled in reducing 2x Laemmli sample buffer (120 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 100 mM dithiothreitol, and 0.02% bromophenol blue). Equal volumes of lysate were run on Criterion XT Bis-Tris gels (4-12%; Bio-Rad) at 170 V for 55 min using 1x XT-MES buffer (Bio-Rad), transferred to nitrocellulose membranes using the BioRad Trans-Blot Turbo transfer system (Bio-Rad). Membranes were blocked for 1 h with 5% non-fat dried milk in TBS-T (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, and 0.05% Tween-20). After overnight incubation with primary antibody at 4 °C, membranes were washed and incubated for 1 h with secondary antibody. CCL3 and β-actin were used as loading control. Supersignal West Pico and Femto chemiluminescence reagent (Thermo Fisher scientific) was used for detection with a ChemiDoc MP system (Bio-Rad). Signal intensities were quantified with Image Lab software v5.0 (Bio-Rad).

2.6. Reverse transcription quantitative PCR (RT-qPCR)

The reverse transcription quantitative PCR (RT-qPCR) assays for the detection of TMPRSS2 were performed using the Quantstudio 5 Real-time PCR system (Applied Biosystems). Premixes were prepared for each amplification reaction, using TaqMan Fast Virus 1-Step Master Mix (Cat. n° 4444434, Thermo Fisher Scientific) according to the manufacturer’s protocol. The TaqMan gene expression assay for TMPRSS2 was obtained from Thermo Fisher Scientific (Hs01122322_m1). Standard curve DNA fragments were obtained via PCR of a full-length TMPRSS2 gene has been described in detail in a recent report (Vanhulle et al., 2022).

The duplex RT-qPCR assay for the detection of SARS-CoV-2 E and N gene has been described in detail in a recent report (Vanhulle et al., 2022).

2.7. Transient transfection

HEK293T cells were seeded at 400,000 cells/mL and incubated overnight at 37 °C prior to transfection the next day. Lipofectamine LTX (Invitrogen) was used for the transfection of plasmid DNA according to the manufacturer’s protocol.

2.8. Cell-cell fusion assay

U87.ACE2+ cells were plated (20,000 cells/well of a 96-well plate) and incubated for 2 days at 37 °C to become a confluent cell monolayer. In parallel, HEK293T cells were transfected with transfection mixtures containing 2.5 μg pCAGGS.SARS-CoV-2.SA19_fpl.mNG2(11)_opt plasmid encoding for SARS-CoV-2 spike protein. The next day, the transfected HEK293T cells were collected, resuspended, and counted on a Luna automated cell counter (Logos Biosystems), and administered to the U87.ACE2+ cells (20,000 cells/well). Fusion events were visualized using the IncuCyte® S3 Live-Cell Analysis System (Sartorius). Phase contrast and GFP images (4 per well) were taken using a 20x objective lens at 10 min intervals for a 5 h period, and 1 h intervals afterwards. Image processing was performed using the IncuCyte software.

2.9. Wild type virus infection assays

All virus-related work was conducted in the high-containment biosafety level 3 facilities of the Rega Institute from the Katholieke Universiteit (KU) Leuven (Leuven, Belgium), according to institutional guidelines. One day prior to the experiment, U87.ACE2+ cells were seeded at 20,000 cells/well in 96 well-plates. Serial dilutions of the test compound were prepared in cell infectious media (DMEM + 2% FCS), overlaid on cells, and then virus was added to each well (MOI indicated in the figure legends). Cells were incubated at 37 °C under 5% CO2 for the duration of the experiment. Viral cytopathic effect and GFP expression were scored in a blinded manner at different time points post infection, and the supernatants were collected and stored at −20 °C.

2.10. Flow cytometry

For the cell surface staining of transfected HEK293T cells, cells were collected, washed in PBS, resuspended, transferred to tubes and samples were centrifuged in a cooled centrifuge (4 °C) at 500 g for 5’. After removal of the supernatant, cells were incubated with the primary (anti-Spike) antibody (30’ at 4 °C), washed in PBS, followed by a 30 min incubation at 4 °C with the secondary (labeled) antibody, and washed again. Finally, samples were stored in PBS containing 2% formaldehyde (VWR Life Science AMRESO). For the intracellular staining of infected U87.ACE2+ cells, cells were collected at different time points as indicated in the figure legends, and the Fixation/Permeabilization kit from BD Biosciences was used (Cat n° 554714). At the time of collection, supernatant was removed, and cells were washed in PBS. Then, trypsin (0.25%) was added and plates were incubated for 3’ at 37 °C to detach the cells from the plate, followed by the addition of cold culture medium with 2% FCS. Next, cells were resuspended, transferred to tubes and samples were centrifuged in a cooled centrifuge (4 °C) at 500 g for 5’. After removal of the supernatant, cells were fixed and permeabilized by the addition of 250 μL of BD Cytofix/Cytoper buffer and incubated at 4 °C for 20’. Samples were washed twice with Perm/Wash buffer before the addition of the primary (anti-Nucleocapsid) antibody (0.5 μg per sample). After a 30 min incubation at 4 °C, samples were washed twice in BD Perm/Wash buffer, followed by a 30 min incubation at 4 °C with the secondary (labeled) antibody, and washed again. Finally, samples were stored in PBS containing 2% formaldehyde (VWR Life Science
Acquisition of all samples was done on a BD FACSCelesta flow cytometer (BD Biosciences) with BD FACSDiva v8.0.1 software. Flow cytometric data were analyzed in FlowJo v10.1 (Tree Star). Subsequent analysis with appropriate cell gating was performed to exclude cell debris and doublet cells, in order to acquire data on living, single cells only.

2.11. MTS-PES assay

Four days after infection, the cell viability of mock- and virus-infected cells was assessed spectrophotometrically via the in situ reduction of the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt, using the CellTiter 96 AQeous One Solution Cell Proliferation Assay (Promega), as described before (Vermeire et al., 2004). The absorbances were read in an eight-channel computer-controlled photometer (Multiscan Ascent Reader, Labsystem, Helsinki, Finland) at two

Fig. 1. U87 cells have no detectable endogenous ACE2 expression but high levels of Cathepsin B. A) Different cell lines were analyzed for ACE2 expression by immunoblotting, with β-actin as loading control. B) Same as in (A) but with the stably ACE2 transduced U87 cells, tested at an early (# 1) or late (# 32) passage of the cells. The transduced U87 cells stably express ACE2 at a very high level as compared to endogenous ACE2 in the Vero E6 cells. The same immunoblot is used for panel A and B, but with a longer exposure time for panel A in order to visualize the faint band in the Calu-3 sample. C) Comparative qPCR analysis of TMPRSS2 mRNA levels in different cells. Graph shows individual copy numbers/μl of 3 technical replicates (n = 3) as calculated from a TMPRSS2 standard. The TMPRSS2 level in Vero E6 cells was below detection limit. D) Different cell lines were analyzed for Cathepsin L (CTSL; left) and Cathepsin B (CTSB; right) expression by immunoblotting, with clathrin as loading control. For CTSL, different species are detected (indicated by the bracket): Pro-CTSL (41 kDa), glycosylated mature CTSL (31 kDa) and non-glycosylated mature CTSL (25 kDa), whereas only the Pro-CTSB form (42 kDa) is visualized. M: molecular marker in kDa, UD: undetectable.
wavelengths (490 and 700 nm). The optical density (OD) of the samples was compared with sufficient cell control replicates (cells without virus and drugs) and virus control wells (cells with virus but without drugs). The median inhibitory concentration (IC50), or the concentration that inhibited SARS-CoV-2-induced cell death by 50%, was calculated from the concentration–response curve.

2.12. Statistical analysis

Data were visualized as means ± standard deviation (SD) and were analyzed by making use of the GraphPad Prism v8.3.0 software. Data were analyzed with unpaired t-tests to compare Wuhan with Omicron. P-values below 0.05 were considered statistically significant.

3. Results

3.1. Generation of a stably ACE2-transduced U87 cell line

In our search for cells that can be used as an in vitro model for SARS-CoV-2 infection and high-throughput evaluation of antiviral drugs, we first tested different cell lines that were available in our antiviral screening platform (Sinii et al., 2017) for their sensitivity to SARS-CoV-2 infection. One of the candidates was the glioblastoma cell line U87 that in previous work (Princen et al., 2004; Høst et al., 2003) has been reported as being highly valuable for Human Immunodeficiency Virus (HIV) research, based on the strong cytopathic effect (CPE) induced in these U87 cells. Preliminary experiments with U87 cells did not result in successful infection with SARS-CoV-2 (data not shown).

Therefore, we determined the cellular expression of ACE2, known as the main receptor for SARS-CoV-2 (Hoffmann et al., 2020; Wu et al., 2020a; Zhou et al., 2020; Wrapp et al., 2020). As shown in Fig. 1A, basal level of ACE2 was undetectable in U87 cells, as measured by immunoblotting, whereas in control Calu-3 cells traces of ACE2 protein could be visualized. In contrast, Vero E6 cells expressed endogenous ACE2 at detectable amounts. Thus, we subsequently introduced the coding sequence for ACE2 in the U87 cells to enhance their sensitivity to SARS-CoV-2. Briefly, cells were stably transduced with a lentiviral vector that encodes for ACE2. After clonal expansion, the cells – designated as U87.ACE2 – were evaluated for their ACE2 protein levels. As shown in Fig. 1B, the U87.ACE2 cells were successfully transduced with ACE2 as evidenced by the very dense protein band on the immunoblot that corresponded to the ACE2 receptor. Furthermore, passaging of the cells for several months did not impact the high ACE2 expression level (Fig. 1B), which demonstrated that the U87.ACE2 cells were stably expressing high amounts of the SARS-CoV-2 receptor of interest.

Following ACE2 binding, the spike protein also needs priming by cellular proteases before membrane fusion and cellular entry of the virus can take place (Hoffmann et al., 2020; Laporte et al., 2021; Shang et al., 2020; Evans and Liu, 2021). Thus, we additionally measured the expression of TMPRSS2 and CTSL/L in the U87.ACE2 cells. As multiple attempts with different antibodies did not result in successful and reliable immunoblotting of TMPRSS2, we chose quantitative PCR (qPCR) as an alternative for the detection of endogenous TMPRSS2. As shown in Fig. 1C, U87.ACE2 cells had detectable mRNA levels of TMPRSS2, comparable to that of A549 cells, but clearly less than what is measured in Calu-3 cells. In line with other reports (Murgolo et al., 2021; Laporte et al., 2021), our qPCR data verified that Vero E6 are deficient in the high abundance of CTSB and detectable levels of CTSL suggest the potential for an endocytic pathway for SARS-CoV-2 entry in the U87. ACE2 cells.

Next, we determined if the U87.ACE2 cells could be infected with wild-type SARS-CoV-2 virus. Therefore, the U87.ACE2 cells were exposed to SARS-CoV-2 (strain 20A.EU2) and microscopically evaluated for cytopathic effect (CPE). As depicted in Fig. 3A, strong CPE was observed after 3 days post infection when a multiplicity of infection (MOI) of 0.3 or 0.03 was used. Moreover, the virus-induced CPE resulted in a complete destruction of the cell monolayer (see movie in Supplementary Fig. 1). This fusion event already manifested within a few hours of cell overlay and depended on the complementary expression of ACE2 and S. This was evidenced by the absence of cell-cell fusion either when U87.ACE2 cells were combined with non-transfected HEK293T cells, or when receptor negative U87 control cells were combined with S-expressing HEK293T cells (Fig. 2C).

Supplementary video related to this article can be found at https://doi.org/10.1016/j.antiviral.2022.105342

3.2. U87.ACE2 cells readily fuse with SARS-CoV-2 Spike expressing HEK293T

Having a U87.ACE2 cell line established, we next determined if these cells express a functional ACE2 receptor that can activate the SARS-CoV-2 Spike (S) protein for membrane fusion. Therefore, we assessed the cell-cell fusion capability of the U87.ACE2 cells with cells expressing the S protein of SARS-CoV-2 (see scheme in Fig. 2A). Briefly, HEK293T cells were transfected with a plasmid encoding for a codon-optimized S protein of SARS-CoV-2 (Wuhan strain). In parallel, U87.ACE2 cells were plated in a 96-well plate to generate a confluent cell layer. Next, the transfected HEK293T cells, expressing the S protein at their cell surface in sufficient amount (Fig. 2B), were administered to the U87.ACE2 cells. As depicted in Fig. 2C, a successful fusion between the U87.ACE2 cells and S-expressing HEK293T cells was obtained, leading to the formation of many fused multinucleated giant cells (syncytia), that ultimately resulted in the complete destruction of the cell monolayer (see movie in Supplementary Fig. 1). This fusion event already manifested within a few hours of cell overlay and depended on the complementary expression of ACE2 and S. This was evidenced by the absence of cell-cell fusion either when U87.ACE2 cells were combined with non-transfected HEK293T cells, or when receptor negative U87 control cells were combined with S-expressing HEK293T cells (Fig. 2C).
produced virions budding from the infected cells (Fig. 4B). Released virus particles could be detected as early as 14 h p.i. and, at 18 h p.i. an nearly three log increase in viral RNA was obtained (Fig. 4B).

3.4. U87.ACE2+ cells can be utilized for screening of anti-SARS-CoV-2 agents

Having successfully developed a cell line that is highly permissive to SARS-CoV-2 and that produces full-blown CPE, we next determined if this cell line could be implemented in an antiviral screening platform. Thus, the U87.ACE2+ cells were seeded in 96-well plates, treated with test compounds, and exposed to SARS-CoV-2. As proof-of-concept, we first tested Remdesivir (GS-5734), a nucleotide analog prodrug that inhibits the SARS-CoV-2 RNA dependent RNA polymerase (RdRp) (Murgo et al., 2021; Fredisnyah et al., 2021; Zhang and Tang, 2021; Wang et al., 2020; Choy et al., 2020), and a spike-neutralizing antibody (R001), acting as an SARS-CoV-2 entry inhibitor (Vanhulle et al., 2022). At 2 days p.i., samples were collected and analyzed, either by flow cytometry (Fig. 5A) or by duplex RT-qPCR (Fig. 5B). Both techniques demonstrated a full protection of SARS-CoV-2 replication by a 2 μM Remdesivir treatment, and a profound inhibition of virus entry by the addition of 10 μg/ml R001 antibody. Furthermore, RT-qPCR analysis on a dilution range of Remdesivir revealed a clear concentration-dependent antiviral effect of Remdesivir in SARS-CoV-2 infected U87.ACE2+ cells,
with IC₅₀ values in the low nanomolar range (Fig. 5C). In fact, in the U87.ACE2⁺ cells, Remdesivir was equally potent against the original Wuhan strain and the European A2 strain (20A.EU2) (Fig. 5C).

Finally, in view of a high-throughput antiviral screening application, we explored a colorimetric read-out of the SARS-CoV-2 infected U87.ACE2⁺ cells. First, a density range of the cells was evaluated in our MTS-PES assay to assess their ability for in situ reduction of the tetrazolium compound MTS. This cell dilution range revealed a clear density-dependent step-wise difference in optical density (OD), roughly between 100 and 10,000 cells/well (Fig. 6A). Also, a longer incubation time (3 days) of the U87.ACE2⁺ cells returned a comparable result with maximum values plateauing at 12,500 cells/well, and minimum values below 500 cells/well. Next, the U87.ACE2⁺ cells were exposed to a dilution range of SARS-CoV-2 (20A.EU2 strain), and CPE was assessed spectrophotometrically. As depicted in Fig. 6B, a clear difference in OD between virus-infected and mock-infected control cells was obtained, in a reproducible manner (4 replicate wells), and resulted in a virus concentration-dependent change in OD-values (Fig. 6B). Furthermore, the colorimetric read-out could be easily applied to determine the cytotoxicity (Fig. 6C and Supplementary Fig. 3) and antiviral activity (Fig. 6D) of Remdesivir. Full protection of virus-exposed U87.ACE2⁺ cells was obtained with Remdesivir at concentrations as low as 80 nM, whereas the next compound dilution (16 nM) evoked a complete CPE. Based on these OD values an IC₅₀ value of 35 nM could be calculated for Remdesivir, which corresponded well with the value obtained through RT-qPCR analysis (Fig. 5C).

In the context of the continuous identification of new circulating SARS-CoV-2 variants, our CPE reduction assay with the U87.ACE2⁺ cells should also be applicable to new arising SARS-CoV-2 mutants. To present a complete analysis of our U87.ACE2⁺ cells in terms of susceptibility to SARS-CoV-2, we exposed the U87.ACE2⁺ cells to different SARS-CoV-2 variants of concern available in our laboratory (Vanhulle et al., 2022). As shown in Fig. 7A and B, our cells could be readily infected by all tested variants, including the recent circulating Omicron variant (Planas et al., 2022). Furthermore, all these SARS-CoV-2 variants induced strong CPE that could be exploited to evaluate antiviral compounds by our MTS-PES assay. A side-by-side comparison in the U87.ACE2⁺ cells of the original Wuhan strain with the latest Omicron variant revealed a significant improved infectivity of Omicron relative to Wuhan as quantified by MTS (Fig. 7B) and by RT-qPCR analysis (Fig. 7C), suggesting a productive endocytic viral entry pathway in the U87.ACE2⁺ cells as has been proposed for Omicron (Zhao et al., 2021; Meng et al., 2022). Interestingly, Remdesivir proved to remain active also in the Omicron-infected U87.ACE2⁺ cells. In addition, Nirmatrelvir (PF-07321332), an irreversible inhibitor of SARS-CoV-2 viral main protease Mpro, also exerted antiviral activity in the nanomolar range, as well as Molnupiravir (MK-4482 or EIDD-2801), a nucleoside analogue prodrug, although with at slightly higher IC₅₀ value in the low micromolar range (Fig. 7D and Supplementary Fig. 3).

4. Discussion

Based on the interesting characteristics (i.e., rapid and full blown CPE) of the U87 cells used in previous HIV work (Princen et al., 2004; Hatse et al., 2001), we assessed in our current study the feasibility of employing U87 cells for the infection with SARS-CoV-2. By simply overexpressing ACE2 in the U87 cells we generated a human glioblastoma cell line that became highly permissive for SARS-CoV-2. These U87.ACE2⁺ cells initiated productive viral replication that induced a severe CPE, which in turn could be successfully exploited as an easy colorimetric read-out of viral infection.

Despite the numerous reports on COVID-19, it is still debatable if SARS-CoV-2 invades the Central Nervous System (CNS) via olfactory neurons (Brann et al., 2020) and infects neurons and glia of the CNS (Zhan et al., 2021; Jacob et al., 2020; Song et al., 2021; Dobrindt et al., 2022). As shown in Fig. 7A and B, our cells could be readily infected by all tested variants, including the recent circulating Omicron variant (Planas et al., 2022). Furthermore, all these SARS-CoV-2 variants induced strong CPE that could be exploited to evaluate antiviral compounds by our MTS-PES assay. A side-by-side comparison in the U87.ACE2⁺ cells of the original Wuhan strain with the latest Omicron variant revealed a significant improved infectivity of Omicron relative to Wuhan as quantified by MTS (Fig. 7B) and by RT-qPCR analysis (Fig. 7C), suggesting a productive endocytic viral entry pathway in the U87.ACE2⁺ cells as has been proposed for Omicron (Zhao et al., 2021; Meng et al., 2022). Interestingly, Remdesivir proved to remain active also in the Omicron-infected U87.ACE2⁺ cells. In addition, Nirmatrelvir (PF-07321332), an irreversible inhibitor of SARS-CoV-2 viral main protease Mpro, also exerted antiviral activity in the nanomolar range, as well as Molnupiravir (MK-4482 or EIDD-2801), a nucleoside analogue prodrug, although with at slightly higher IC₅₀ value in the low micromolar range (Fig. 7D and Supplementary Fig. 3).
of active viral replication of SARS-CoV-2 in the U87 cells, given that GFP expression depends on the RdRp activity of the virus in the infected cells. Altogether, we concluded that the parent U87 cells are non-permissive to SARS-CoV-2.

Undoubtedly, successful infection of SARS-CoV-2 is correlated to cell surface expression of Angiotensin-Converting Enzyme 2 (ACE2), the well-accepted main receptor for SARS-CoV-2 (Hoffmann et al., 2020; Wu et al., 2020a; Zhou et al., 2020; Wrapp et al., 2020; Yan et al., 2020; Walls et al., 2020). An earlier report showed that in the brain, ACE2 is expressed only in endothelium and vascular smooth muscle cells (Hamming et al., 2004). Also, a single-cell sequencing study on glioblastoma demonstrated a relatively high expression of ACE2 in endothelial cells, bone marrow mesenchymal stem cells, and neural precursor cells (Wu et al., 2020b). In that study, Wu et al. (2020b) reported a low but detectable protein level of ACE2 in glioma cell lines, including the U87 cells, whereas our immunoblot analysis did not detect any ACE2 in U87 cells. Nevertheless, our study clearly demonstrated that ACE2 needs to be expressed abundantly before glioma cells become permissive to SARS-CoV-2. Supplementary, our data also reveal that (temporarily) upregulation of ACE2 in glioma cells (e.g., in some malignancies) might turn neuronal cells into highly permissive target cells for SARS-CoV-2. Thus, the U87.ACE2+ cells might represent useful tools.

Fig. 4. U87.ACE2+ cells actively replicate wild-type SARS-CoV-2. A). U87 and U87.ACE2+ cells were exposed to different doses of SARS-CoV-2 (Wuhan strain). Samples were collected at 16 h post infection and 5,000–6,000 cells were analyzed by flow cytometry. Cells were stained for intracellular nucleoprotein (N) expression. Dot plots show N expression in noninfected (lower left quadrant) and infected (lower right quadrant) cells. The numbers in each quadrant refer to the distribution of the cells (i.e., percentage of total cell population). The dot plot in grey (left panel) represents the noninfected cell control. B). U87.ACE2+ cells were exposed to SARS-CoV-2 (20A.EU2 strain; MOI 5) for 1 h (indicated by grey boxed V). Next, cells were washed extensively to remove unbound virus and were given fresh medium. Supernatant was collected at the indicated time points and a duplex RT-qPCR was performed to quantify the copy numbers of the N and E genes. The dotted horizontal line refers to the background signal. For each sample, the average (mean ± SD) of two technical replicates is given (n = 2), plotted on a log10 scale.
to disentangle the entry and replication of SARS-CoV-2 in the CNS.

The viral spike protein of SARS-CoV-2 drives ACE2 receptor binding and subsequent membrane fusion of the viral envelope with the cell membrane. However, in order to initiate this membrane fusion reaction, the S protein needs to be proteolytic cleaved at the S2’ cleavage site to make its fusion peptide accessible for membrane insertion. Several different proteases have been identified that can prime SARS-CoV-2 S, either at the plasma membrane (TMPRSS2) or in endosomes/lysosomes (cathepsins) (Hoffmann et al., 2020; Laporte et al., 2021; Tang et al., 2020; Muralidar et al., 2021). This flexibility in protease usage and entry route appears to be a consistent strategy used by coronaviruses (Murgolo et al., 2021; Evans and Liu, 2021). Thus, besides ACE2 expression viral tropism will also largely depend on the availability of those cellular proteases, generating a cell type-dependency for SARS-CoV-2 (Chu et al., 2020; Evans and Liu, 2021). The U87 glioblastoma cells used in our study did express both TMPRSS2 and CTSB/L. Whereas the level of TMPRSS2 in the U87.ACE2+ cells was low as compared to the lung epithelia-derived Calu-3 cell line (often considered as a physiologically relevant cell type for SARS-CoV-2) (Laporte et al., 2021), it might still be sufficient to initiate cell surface SARS-CoV-2 entry. This is in contrast with the widely-used Vero E6 cells which are human TMPRSS2-deficient, as confirmed by our results. However, levels of CTSB were extremely high in the U87.ACE2+ cells, whereas Vero E6 cells had nearly detectable CTSB, and vice versa, protein levels of CTSL were high in Vero E6 cells and much lower in the U87.ACE2+ cells. These data suggest that the U87.ACE2+ cells might accommodate an endosomal entry route for SARS-CoV-2, and if so, that CTSB can also be a relevant cysteine protease for S priming. In that perspective, the U87.ACE2+ cells can be considered as a valuable additional cell line for further cathepsin studies in SARS-CoV-2 research. Furthermore, based on recent reports of the current circulating Omicron variant, demonstrating that SARS-CoV-2 Omicron infection is not enhanced by TMPRSS2 but is largely mediated via the endocytic pathway (Zhao et al., 2021; Meng et al., 2022), more attention should be given to the endosomal entry route for SARS-CoV-2. Of note, our U87.ACE2+ cells remained highly permissive for other SARS-CoV-2 variants of concern, including the Omicron variant. In fact, we observed a significant enhanced infectivity of Omicron in the U87.ACE2+ cells as compared to the Wuhan strain, suggesting that the U87.ACE2+ cells support an endosomal entry route.

An important parameter in antiviral screening is the determination of the cytotoxic effect of compounds in addition to their antiviral activity.
Antiviral Research 203 (2022) 105342

E. Vanhulle et al.

potency. Whereas the Vero E6 cells are known for high resistance to cellular toxicity, the U87.ACE2+ cells showed reasonable sensitivity (Supplementary Fig. 3), making these cells more interesting for the selection of potential candidate drugs with promising therapeutic indices that can be further explored in follow-up in vivo studies. In addition, Vero E6 cells might be less suitable for the antiviral screening of small molecules due to their limited capacity to metabolize drugs compared to human-derived cells, as demonstrated for remdesivir in several reports (Uemura et al., 2021; Chiu et al., 2022; Ramirez et al., 2021) and confirmed by our study (Supplementary Fig. 3). Moreover, the antiviral potency of both remdesivir and nirmatrelvir was approximately 1,000 times higher in the U87.ACE2+ cells as compared to the Vero E6 cells.

Fig. 6. Colorimetric analysis of SARS-CoV-2 infected U87.ACE2+ cells. A) U87.ACE2+ cells were plated in 96-well plates at a 1:2 dilution range (starting from 50,000 cells/well) and incubated for 1 day (left) or 3 days (right) before analysis by MTS-PES. Graphs show optical density (OD) values (mean ± SD; n = 2). The dotted line represents the OD value measured for medium only. B) U87.ACE2+ cells were exposed to a virus stock dilution range (1:10) of SARS-CoV-2 strain 20A.EU2 (starting from a 10^3 dilution), incubated for 4 days and analyzed by MTS-PES. On the left is a picture taken from the 96-well plate after the in situ reduction of the tetrazolium compound MTS, for 4 replicates. The wells indicated by the black rectangle represent the virus-infected cells. The 2 columns outside the black rectangle are the mock-infected control cells. The graph on the right shows the corresponding OD values (mean ± SD; n = 4). The dotted blue line represents the OD value measured for cells only without virus (CC). The dotted black line represents the OD value measured for medium only. C) U87.ACE2+ cells were incubated with Remdesivir, incubated for 3 days, and analyzed by MTS-PES. Graph shows OD values (mean ± SD; n = 2) for a concentration range of compound, with calculated cytotoxic CC50 value of Remdesivir. The blue dotted line represents the cell control (CC) and the black dotted line represents the OD value measured for medium only. D) U87.ACE2+ cells were infected with SARS-CoV-2 (Wuhan strain, MOI 0.1) in absence or presence of Remdesivir, incubated for 4 days and analyzed by MTS-PES. Graph shows OD values for a concentration range of compound, with calculated IC50 value of Remdesivir. The blue dotted line represents the cell control (CC) and the red line the virus control (VC).
indicating that potential new SARS-CoV-2 antivirals can be more successfully identified in the U87.ACE2+ cells as compared to the Vero E6 cells.

Finally, one of the main advantages of the human U87.ACE2+ cells over existing SARS-CoV-2 infection models is their ability to induce a rapid (within 2 days) and full-blown CPE with complete cell lysis (e.g., compared to Vero E6 cells that slowly present clear CPE as cell detachment rather than cell lysis) in a consistent and reproducible way. This feature of cell destruction is of great value for an easy and clear-cut read-out in a CPE reduction assay, especially when a colorimetric

Fig. 7. U87.ACE2+ cells are permissive to different SARS-CoV-2 variants of concern and preserve remdesivir activity against Omicron. A) U87.ACE2+ cells were exposed to a virus stock dilution range (1:10) of different SARS-CoV-2 variants of concern (starting from a 10^3 x dilution), incubated for 4 days and analyzed by MTS-PES. The blue dotted line represents the cell control (CC) and the dotted black line represents the OD value measured for medium only. Graphs show optical density (OD) values (mean ± SD; n = 2). B) U87.ACE2+ cells were exposed to a virus stock dilution range (1:10) of SARS-CoV-2 variant Wuhan and Omicron (starting at an MOI = 1), incubated for 4 days and analyzed by MTS-PES. The blue dotted line represents the cell control (CC). Graphs show optical density (OD) values (mean ± SD; n = 3). *, P < 0.05; Unpaired t-test. C) Same as in (B) but supernatant was collected at 24 h p.i. and RT-qPCR was performed to quantify the copy numbers of the E gene and to determine the amount of virion release into the culture medium. For each sample, the average (mean ± SD) of two technical replicates is given (n = 2), plotted on a log10 scale. *, P < 0.05; Unpaired t-test. D) U87.ACE2+ cells were infected with SARS-CoV-2 (Omicron strain, MOI 0.08) in absence or presence of Remdesivir, Nirmatrelvir or Molnupiravir, incubated for 4 days and analyzed by MTS-PES. OD values were used to calculate the % inhibition of viral replication and to plot a concentration-response curve. For each compound, the IC50 value is given. Values are mean ± SD; n = 4.

E. Vanhulle et al.
quantification of CPE-induced reduction in cell viability is utilized. Thus, infection of glioblastoma cells might serve as an easy and low-cost model for testing drugs in high-throughput screening platforms, and hopefully contribute to the development of effective antiviral countermeasures to tackle SARS-CoV-2.

Declarations of interest

None.

Author contributions

K.V., E.V. and J.S. designed research; E.V., A.C., B.P., J.S. and S.N. performed research; E.V., S.N. and K.V. analyzed the data; E.V. and K.V. wrote the manuscript; P.M. contributed new reagents/analytic tools. All of the authors discussed the results and commented on the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of interests

The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank Geert Schoofs for technical support to the flow cytometry experiments and Dominique Schols for financial support. Due to the rapid progress in the field, the authors apologize for the ignorance of other relevant works.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.antiviral.2022.105342.

References

Bestle, D., Heindl, M.R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., et al., 2020. TMRPSS2 and furin are both essential for protolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 3 (9). https://doi.org/10.26508/lsa.20200786.
Bielarz, V., Willemart, K., Avalosse, N., De Swert, K., Lotfi, R., Lejeune, N., et al., 2021. Highly efficient and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. EMBO J. 39 (20), e106230 https://doi.org/10.15252/embj.2020106230.
Brann, D.H., Tukakara, T., Weinreb, C., Lipovek, M., Van den Berge, K., Gong, B., et al., 2020. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 6 (31) https://doi.org/10.1126/sciadv.abc5801.
Bullen, C.K., Hogberg, H.T., Bahadirli-Talbott, A., Bishai, W.R., Hartung, T., Keuthan, C., et al., 2021. Development and optimization of a high-throughput screening assay for SARS-CoV-2 infecting the human choroid plexus and disrupts the blood-CSF barrier in human lung cells. PLos Pathog. 17 (4), e1009550 https://doi.org/10.1371/journal.ppat.1009550.
Buck, A., Eftekhari, M., Gwernan-Jones, A., Mathieson, M., Crook, A.L., et al., 2020. Identification of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV infection. J. Infect. Dis. 221 (1), 102436. https://doi.org/10.1093/infdis/jiab504.
Pellerin, L., Albecka, A., Mallory, D.L., Kellner, M.J., Paul, D., Carter, A.P., et al., 2020. Susceptibility of neuroblastoma and glioblastoma cell lines to SARS-CoV-2 infection. stemcr.2020.10.001 e5. https://doi.org/10.1016/s2666-5247(20)30004-5.
Pellegrini, L., Albecka, A., Muller, P.N., Gabriel, E., Abida-Islam, P., Muller-Schiffmann, A., et al., 2020. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 39 (20), e106230 https://doi.org/10.15252/embj.2020106230.
Ramirez, S., Fernandez-Antunez, C., Galli, A., Underwood, A., Pham, L.V., Ryberg, L.A., et al., 2020. Overcoming CoV-2 infection in human bronchial organoids facilitates the screening of compounds inhibiting viral replication. Antimicrob. Agents Chemother. 65 (7), e00972-21. https://doi.org/10.1128/AAC.00972-21.
Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A.V., Skriabine, S., et al., 2021. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J. Med. Virol. 93 (3), 1403-1408. https://doi.org/10.1002/jmv.26397.
Tang, T., Bidon, M., Lecron, J.C., Ziegler, J., Zhang, Z., et al., 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11 (1), 1620. https://doi.org/10.1038/s41467-020-15562-9.
Vanhulle, E., et al., 2022. Development and optimization of a high-throughput screening assay for SARS-CoV-2 infecting the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 27 (6), 937-950. https://doi.org/10.1016/j.stem.2020.09.016 e9.
Uemura, K., Sasaki, M., Sanaki, T., Toba, S., Takahashi, Y., Orba, Y., et al., 2021. MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. Sci. Rep. 11 (1), 5376. https://doi.org/10.1038/s41598-021-84882-7.

Vanhulle, E., Provinciael, B., Stroobants, J., Camps, A., Maes, P., Vermeire, K., 2022. Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern. Biotechniques 72 (6), 1–8. https://doi.org/10.2144/btn-2022-0018.

Vermeire, K., Princen, K., Hatse, S., De Clercq, E., Dey, K., Bell, T.W., et al., 2004. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 18 (16), 2115–2125.

Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. https://doi.org/10.1016/j.cell.2020.02.058. Cell.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al., 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30 (3), 269–271. https://doi.org/10.1038/s41422-020-0282-0.

Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., et al., 2020a. A new coronavirus associated with human respiratory disease in China. Nature 579 (7798), 265–269. https://doi.org/10.1038/s41586-020-0698-3.

Wu, B., Wang, W., Wang, H., Zou, Q., Hu, B., Ye, L., et al., 2020b. Single-cell sequencing of glioblastoma reveals central nervous system susceptibility to SARS-CoV-2. Front. Oncol. 10, 566599. https://doi.org/10.3389/fonc.2020.566599.

Yadav, D.K., Singh, D.D., Han, I., Kumar, Y., Choi, E.H., 2021. Current potential therapeutic approaches against SARS-CoV-2: a review. Biomedicines 9 (11). https://doi.org/10.3390/biomedicines91111260.

Yang, L., Han, Y., Nilsson-Payant, B.E., Gupta, V., Wang, P., Duan, X., et al., 2020. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 27 (1), 125–136. https://doi.org/10.1016/j.stem.2020.06.015 e7.

Zhao, H., Lu, L., Peng, Z., Chen, L.L., Meng, X., Zhang, C., et al., 2021. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells. Emerg. Microb. Infect. 1–18 https://doi.org/10.1080/22221751.2021.2023329.

Zhong, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7.